Spyre Therapeutics (NASDAQ:SYRE) Insider Sells 400 Shares of Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE) insider Heidy King-Jones sold 400 shares of Spyre Therapeutics stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $90.00, for a total transaction of $36,000.00. Following the completion of the sale, the insider owned 2,845 shares in the company, valued at approximately $256,050. This trade represents a 12.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Heidy King-Jones also recently made the following trade(s):

• On Tuesday, September 1st, Heidy King-Jones sold 27,999 shares of Spyre Therapeutics stock. The stock was sold at an average price of $87.31, for a total transaction of $2,444,592.69.

Spyre Therapeutics Stock Up 0.2%

Shares of NASDAQ:SYRE traded up $0.20 on Thursday, hitting $87.25. The company had a trading volume of 1,054,184 shares, compared to its average volume of 1,063,422. The firm’s 50-day simple moving average is $98.03 and its two-hundred day simple moving average is $74.53. Spyre Therapeutics, Inc. has a 1 year low of $14.51 and a 1 year high of $110.18. The firm has a market capitalization of $7.67 billion, a price-to-earnings ratio of -44.74 and a beta of 2.99.

Spyre Therapeutics (NASDAQ:SYRE) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.40. Equities research analysts anticipate that Spyre Therapeutics, Inc. will post -2.62 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on SYRE. Mizuho raised their target price on Spyre Therapeutics from $84.00 to $120.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Wolfe Research cut shares of Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Tuesday, July 28th. Wells Fargo & Company upped their target price on shares of Spyre Therapeutics from $90.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Wall Street Zen lowered shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, Robert W. Baird set a $120.00 price target on shares of Spyre Therapeutics in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Spyre Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $109.69.

Institutional Trading of Spyre Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SYRE. Seven Grand Managers LLC purchased a new position in Spyre Therapeutics in the 4th quarter worth approximately $3,276,000. Capital International Investors lifted its position in Spyre Therapeutics by 46.0% in the 4th quarter. Capital International Investors now owns 3,492,541 shares of the company’s stock valued at $114,416,000 after acquiring an additional 1,100,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in Spyre Therapeutics by 32.3% during the 4th quarter. Vanguard Group Inc. now owns 4,035,074 shares of the company’s stock valued at $132,189,000 after purchasing an additional 984,344 shares during the last quarter. UBS Group AG boosted its stake in Spyre Therapeutics by 76.5% during the 4th quarter. UBS Group AG now owns 680,566 shares of the company’s stock valued at $22,295,000 after purchasing an additional 294,977 shares during the last quarter. Finally, Handelsbanken Fonder AB bought a new stake in shares of Spyre Therapeutics in the 2nd quarter worth $2,308,000. 80.39% of the stock is currently owned by institutional investors.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.